84,998 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Purchased by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 84,998 shares of the company's stock, valued at approximately $1,124,000. Polar Asset Management Partners Inc. owned about 0.10% of Syndax Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SNDX. Granahan Investment Management LLC grew its stake in Syndax Pharmaceuticals by 36.2% in the fourth quarter. Granahan Investment Management LLC now owns 905,322 shares of the company's stock worth $11,968,000 after purchasing an additional 240,557 shares during the period. Octagon Capital Advisors LP purchased a new stake in Syndax Pharmaceuticals in the 4th quarter worth $11,951,000. Northern Trust Corp raised its stake in Syndax Pharmaceuticals by 7.5% during the 4th quarter. Northern Trust Corp now owns 792,750 shares of the company's stock valued at $10,480,000 after purchasing an additional 55,144 shares during the period. Algert Global LLC lifted its holdings in shares of Syndax Pharmaceuticals by 65.4% in the fourth quarter. Algert Global LLC now owns 785,632 shares of the company's stock worth $10,386,000 after buying an additional 310,634 shares in the last quarter. Finally, Crestline Management LP grew its position in shares of Syndax Pharmaceuticals by 66.4% during the fourth quarter. Crestline Management LP now owns 713,205 shares of the company's stock valued at $9,429,000 after purchasing an additional 284,667 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts recently commented on SNDX shares. Scotiabank raised their price target on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. StockNews.com raised shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. Citigroup lowered their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. JPMorgan Chase & Co. increased their price objective on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, March 20th. Finally, Guggenheim reissued a "buy" rating and set a $32.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.91.

Syndax Pharmaceuticals Trading Up 13.7%

Shares of NASDAQ:SNDX traded up $1.27 during midday trading on Tuesday, hitting $10.57. The stock had a trading volume of 3,551,520 shares, compared to its average volume of 1,739,784. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.58 and a 1 year high of $25.07. The stock has a 50 day moving average price of $11.97 and a two-hundred day moving average price of $13.94. The company has a market capitalization of $909.52 million, a PE ratio of -2.91 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. The business's revenue for the quarter was up 1900.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.85) EPS. As a group, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).